BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Choi JH, Song MJ, Kim SH, Choi SM, Lee DG, Yoo JH, Shin WS. Effect of moxifloxacin on production of proinflammatory cytokines from human peripheral blood mononuclear cells. Antimicrob Agents Chemother 2003;47:3704-7. [PMID: 14638469 DOI: 10.1128/AAC.47.12.3704-3707.2003] [Cited by in Crossref: 29] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Padrones S, Garcia-Vidal C, Fernández-Serrano S, Fernández A, Masuet C, Carratalà J, Coromines M, Ardanuy C, Gudiol F, Manresa F, Dorca J. Impact of antibiotic therapy on systemic cytokine expression in pneumococcal pneumonia. Eur J Clin Microbiol Infect Dis 2010;29:1243-51. [PMID: 20567869 DOI: 10.1007/s10096-010-0993-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
2 Beisswenger C, Honecker A, Kamyschnikow A, Bischoff M, Tschernig T, Bals R. Moxifloxacin modulates inflammation during murine pneumonia. Respir Res 2014;15:82. [PMID: 25034539 DOI: 10.1186/1465-9921-15-82] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
3 Jiang SW, Whitley MJ, Mariottoni P, Jaleel T, MacLeod AS. Hidradenitis Suppurativa: Host-Microbe and Immune Pathogenesis Underlie Important Future Directions. JID Innov 2021;1:100001. [PMID: 34909706 DOI: 10.1016/j.xjidi.2021.100001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
4 Batra R, Sadhasivam S, Saini S, Gupta S, Bisen RKS, Sinha M, Ghosh S, Jain S. Efficacy and Safety of VB-1953 Topical Gel in Non-Responder Acne Patients with Clindamycin-Resistant Cutibacterium acnes. Drugs R D 2020;20:95-104. [PMID: 32222937 DOI: 10.1007/s40268-020-00299-z] [Reference Citation Analysis]
5 Anderson R, Tintinger G, Cockeran R, Potjo M, Feldman C. Beneficial and Harmful Interactions of Antibiotics with Microbial Pathogens and the Host Innate Immune System. Pharmaceuticals (Basel) 2010;3:1694-710. [PMID: 27713324 DOI: 10.3390/ph3051694] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
6 Weiss T, Shalit I, Blau H, Werber S, Halperin D, Levitov A, Fabian I. Anti-inflammatory effects of moxifloxacin on activated human monocytic cells: inhibition of NF-kappaB and mitogen-activated protein kinase activation and of synthesis of proinflammatory cytokines. Antimicrob Agents Chemother 2004;48:1974-82. [PMID: 15155187 DOI: 10.1128/AAC.48.6.1974-1982.2004] [Cited by in Crossref: 71] [Cited by in F6Publishing: 23] [Article Influence: 3.9] [Reference Citation Analysis]
7 Constantinou CA, Fragoulis GE, Nikiphorou E. Hidradenitis suppurativa: infection, autoimmunity, or both? Ther Adv Musculoskelet Dis 2019;11:1759720X19895488. [PMID: 31908656 DOI: 10.1177/1759720X19895488] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
8 Calbo E, Alsina M, Rodríguez-Carballeira M, Lite J, Garau J. Systemic expression of cytokine production in patients with severe pneumococcal pneumonia: effects of treatment with a beta-lactam versus a fluoroquinolone. Antimicrob Agents Chemother 2008;52:2395-402. [PMID: 18426893 DOI: 10.1128/AAC.00658-07] [Cited by in Crossref: 27] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
9 Jacobsen F, Fisahn C, Sorkin M, Thiele I, Hirsch T, Stricker I, Klaassen T, Roemer A, Fugmann B, Steinstraesser L. Efficacy of topically delivered moxifloxacin against wound infection by Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2011;55:2325-34. [PMID: 21343458 DOI: 10.1128/AAC.01071-10] [Cited by in Crossref: 38] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
10 Frew JW, Hawkes JE, Krueger JG. Topical, systemic and biologic therapies in hidradenitis suppurativa: pathogenic insights by examining therapeutic mechanisms. Ther Adv Chronic Dis 2019;10:2040622319830646. [PMID: 30854183 DOI: 10.1177/2040622319830646] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 9.3] [Reference Citation Analysis]
11 Pardillo FE, Burgos J, Fajardo TT, Dela Cruz E, Abalos RM, Paredes RM, Andaya CE, Gelber RH. Powerful bactericidal activity of moxifloxacin in human leprosy. Antimicrob Agents Chemother 2008;52:3113-7. [PMID: 18573938 DOI: 10.1128/AAC.01162-07] [Cited by in Crossref: 26] [Cited by in F6Publishing: 7] [Article Influence: 1.9] [Reference Citation Analysis]